Statements (64)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:vaccine
|
gptkbp:administered_by |
gptkb:healthcare_professionals
gptkb:individuals injection pharmacies clinical settings community health centers older adults immunocompromised individuals in healthcare settings mass vaccination sites frontline workers mobile clinics people with underlying health conditions |
gptkbp:approves |
gptkb:FDA
|
gptkbp:available_in |
multiple formulations
|
gptkbp:can_be_combined_with |
other vaccines
|
gptkbp:contains |
antigens
|
gptkbp:developed_by |
gptkb:Johnson_&_Johnson
gptkb:Pfizer gptkb:Moderna various pharmaceutical companies |
https://www.w3.org/2000/01/rdf-schema#label |
COVID-19 vaccine booster
|
gptkbp:increased |
antibody levels
|
gptkbp:is_administered_after |
primary vaccination
|
gptkbp:is_available_in |
gptkb:various_countries
|
gptkbp:is_discussed_in |
gptkb:literature
scientific conferences public health forums |
gptkbp:is_evaluated_by |
effectiveness
safety health authorities efficacy long-term effects |
gptkbp:is_linked_to |
community immunity
increased public confidence in vaccines decreased mortality rates reduced transmission lower hospitalization rates |
gptkbp:is_monitored_by |
adverse effects
|
gptkbp:is_part_of |
COVID-19 response
immunization programs vaccination strategy booster campaign |
gptkbp:is_promoted_by |
government agencies
non-profit organizations health organizations international health organizations |
gptkbp:is_promoted_through |
public awareness campaigns
|
gptkbp:is_recommended_after |
initial vaccination series
|
gptkbp:is_recommended_by |
gptkb:CDC
|
gptkbp:is_recommended_for |
elderly individuals
high-risk populations |
gptkbp:is_studied_in |
clinical trials
|
gptkbp:is_subject_to |
regulatory approval
public health guidelines |
gptkbp:is_targeted_at |
gptkb:SARS-Co_V-2
|
gptkbp:is_used_to |
combat COVID-19
|
gptkbp:may_be_given |
after a certain time period
|
gptkbp:provides |
increased immunity
|
gptkbp:requires |
initial vaccination series
|
gptkbp:shown_to_reduce |
severe illness
|
gptkbp:bfsParent |
gptkb:Bio_NTech
|
gptkbp:bfsLayer |
5
|